期刊
JOURNAL OF CANCER
卷 12, 期 9, 页码 2570-2581出版社
IVYSPRING INT PUBL
DOI: 10.7150/jca.53134
关键词
PIM2; oncogene; protein kinase; phosphorylation; inhibitors
类别
资金
- Innovation fund of National Natural Science Foundation of China [81972489]
- National Natural Science Foundation of Shandong Province [ZR2020YQ58]
PIM2 kinase is a key oncogene in multiple cancers, promoting transcriptional activation of genes involved in cell survival, proliferation, and cell-cycle progression. Numerous tumorigenic signaling molecules have been identified as substrates for PIM2 kinase, leading to the development of various inhibitors. PIM2 is poised to become a therapeutic target in cancer treatment in the future.
PIM2 (proviral integration site for Moloney murine leukemia virus 2) kinase plays an important role as an oncogene in multiple cancers, such as leukemia, liver, lung, myeloma, prostate and breast cancers. PIM2 is largely expressed in both leukemia and solid tumors, and it promotes the transcriptional activation of genes involved in cell survival, cell proliferation, and cell-cycle progression. Many tumorigenic signaling molecules have been identified as substrates for PIM2 kinase, and a variety of inhibitors have been developed for its kinase activity, including SMI-4a, SMI-16a, SGI-1776, JP11646 and DHPCC-9. Here, we summarize the signaling pathways involved in PIM2 kinase regulation and PIM2 mechanisms in various neoplastic diseases. We also discuss the current status and future perspectives for the development of PIM2 kinase inhibitors to combat human cancer, and PIM2 will become a therapeutic target in cancers in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据